GlassScriptPhysician profile
Beena Ijaz
NPI 1649453820
$3,285.84
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $439 · 2021: $607 · 2022: $1,022 · 2023: $563 · 2024: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.03 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,059.84 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $312.37 | 2020-2024 | Farxiga |
| Lilly USA, LLC | $205.95 | 2020-2023 | Mounjaro |
| Astellas Pharma US INC | $168.55 | 2020-2023 | Myrbetriq |
| Novo Nordisk INC | $149.07 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $130.88 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $128.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.81 | 2019-2023 | Ofev, Jardiance, Tradjenta |
| Shire North American Group INC | $109.19 | 2019 | |
| Merck Sharp & Dohme LLC | $107.41 | 2019-2022 | |
| Amarin Pharma, INC. | $104.90 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.51 | 2022 | |
| Glaxosmithkline, LLC. | $75.21 | 2020-2022 | |
| Amgen INC. | $72.47 | 2020-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $69.44 | 2019-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $65.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.11 | 2019-2022 | |
| Pfizer INC. | $57.26 | 2023 | |
| Allergan, INC. | $51.96 | 2019-2020 | |
| Alfasigma USA, INC. | $25.97 | 2020 | |
| Dexcom, INC. | $21.11 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $20.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.30 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.55 | 2024 | Unithroid |
| Smith+Nephew, INC. | $12.96 | 2019 | |
| Sumitomo Pharma America, INC. | $12.26 | 2023 | Gemtesa |
| Evoke Pharma, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beena Ijaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.